Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose : clinical implications and strategies for a successful outcome in major depressive disorder
Fagiolini, Andrea (University of Siena School of Medicine)
Cardoner, N. (Narcís) (Institut d'Investigació Biomèdica Sant Pau)
Pirildar, Sebnem (Ege University Medical School)
Ittsakul, Pichai (Mahidol University)
Ng, Bernardo (Mexican Consortium of Neuropsychopharmacology)
Duailibi, Kalil (Santo Amaro University)
El Hindy, Nasser (American Center Neurology and Psychiatry)
Universitat Autònoma de Barcelona

Fecha:	2023
Resumen:	Mental health disorders, especially depressive and anxiety disorders, are associated with substantial health-related burden. While the second-generation antidepressants are widely accepted as first-line pharmacological treatment for major depressive disorder (MDD), patient response to such treatment is variable, with more than half failing to achieve complete remission, and residual symptoms are frequently present. Areas covered: Here, the pharmacodynamics of venlafaxine XR are reviewed in relation to its role as both a selective serotonin reuptake inhibitor (SSRI) and a serotonin-norepinephrine-reuptake inhibitor (SNRI), and we look at how these pharmacodynamic properties can be harnessed to guide clinical practice, asking the question 'is it possible to develop a symptom-cluster-based approach to the treatment of MDD with comorbid anxiety utilizing venlafaxine XR?. ' Additionally, three illustrative clinical cases provide practical examples of the utility of venlafaxine-XR in real-world clinical practice. The place of venlafaxine XR in managing fatigue/low energy, a frequent residual symptom in MDD, is explored using pooled data from clinical trials of venlafaxine XR. Expert opinion: Venlafaxine XR should be considered as a first-line treatment for MDD with or without comorbid anxiety, and there are clear pharmacodynamic signals supporting a symptom cluster-based treatment paradigm for venlafaxine XR.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Anglès
Documento:	Article de revisió ; recerca ; Versió publicada
Materia:	Anxiety ; Depression ; Disorder ; Major depressive ; Monoamines ; Symptom clusters ; Venlafaxine
Publicado en:	Expert Opinion on Pharmacotherapy, Vol. 24 Núm. 15 (2023) , p. 1715-1723, ISSN 1744-7666

DOI: 10.1080/14656566.2023.2242264
PMID: 37501324

10 p, 1.4 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados